{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:05:21Z","timestamp":1789578321742,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.euo.2025.09.002","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T16:02:34Z","timestamp":1763568154000},"page":"967-976","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Systematic Review of Intracavitary Therapies for Upper Tract Urothelial Carcinoma"],"prefix":"10.1016","volume":"9","author":[{"given":"Chris Ho-Ming","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Ka-Wai","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan Ching-Ho","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Siu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9361-2342","authenticated-orcid":false,"given":"Jeremy Yuen-Chun","family":"Teoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.09.002_b0005","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euo.2025.09.002_b0010","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1097\/JU.0000000000003480","article-title":"Diagnosis and management of non-metastatic upper tract urothelial carcinoma: AUA\/SUO guideline","volume":"209","author":"Coleman","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.09.002_b0015","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2023.03.013","article-title":"European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2023 update","volume":"84","author":"Roupret","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.09.002_b0020","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s12894-024-01627-0","article-title":"Chronic renal impairment predicts oncological outcomes in UTUC patients undergoing RNU","volume":"24","author":"Wong","year":"2024","journal-title":"BMC Urol"},{"key":"10.1016\/j.euo.2025.09.002_b0025","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/MOU.0000000000000148","article-title":"Kidney-sparing surgery for upper tract urothelial cancer","volume":"25","author":"Lucca","year":"2015","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.euo.2025.09.002_b0030","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.euros.2023.11.005","article-title":"Current evidence on utility, outcomes, and limitations of endoscopic laser ablation for localized upper urinary tract urothelial carcinoma: results from a scoping review","volume":"59","author":"Giulioni","year":"2024","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euo.2025.09.002_b0035","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1016\/j.clgc.2019.10.015","article-title":"Segmental ureterectomy for upper tract urothelial carcinoma: a systematic review and meta-analysis of comparative studies","volume":"18","author":"Veccia","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2025.09.002_b0040","doi-asserted-by":"crossref","first-page":"4495","DOI":"10.3390\/cancers15184495","article-title":"Modern kidney-sparing management of upper tract urothelial carcinoma","volume":"15","author":"Ghoreifi","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.euo.2025.09.002_b0045","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.juro.2016.03.194","article-title":"Upper urinary tract carcinoma in situ: current knowledge, future direction","volume":"197","author":"Redrow","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.09.002_b0050","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1159\/000020365","article-title":"Bacillus Calmette-Guerin perfusion therapy for the treatment of transitional cell carcinoma in situ of the upper urinary tract","volume":"38","author":"Nonomura","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.09.002_b0055","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1442-2042.2010.02678.x","article-title":"Bacillus Calmette-Guerin treatment of non-muscle invasive bladder cancer","volume":"18","author":"Sylvester","year":"2011","journal-title":"Int J Urol"},{"key":"10.1016\/j.euo.2025.09.002_b0060","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.euf.2023.03.016","article-title":"Mitomycin gel (UGN-101) as a kidney-sparing treatment for upper tract urothelial carcinoma in patients with imperative indications and high-grade disease","volume":"9","author":"Rose","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2025.09.002_b0065","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/JU.0000000000002350","article-title":"Durability of response to primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel: OLYMPUS trial final report","volume":"207","author":"Matin","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.09.002_b0070","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.urology.2004.01.046","article-title":"Long-term effects of bacille Calmette-Guerin perfusion therapy for treatment of transitional cell carcinoma in situ of upper urinary tract","volume":"63","author":"Hayashida","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.euo.2025.09.002_b0075","doi-asserted-by":"crossref","first-page":"221.e9","DOI":"10.1016\/j.urolonc.2024.03.012","article-title":"Sequential endoluminal gemcitabine and docetaxel vs. bacillus Calmette-Guerin for the treatment of upper tract carcinoma in situ","volume":"42","author":"McElree","year":"2024","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2025.09.002_b0080","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0022-5347(17)36117-7","article-title":"Intrarenal bacillus Calmette-Guerin therapy for upper urinary tract carcinoma in situ","volume":"149","author":"Sharpe","year":"1993","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.09.002_b0085","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1097\/JU.0000000000002454","article-title":"Antegrade instillation of UGN-101 (mitomycin for pyelocalyceal solution) for low-grade upper tract urothelial carcinoma: initial clinical experience","volume":"207","author":"Rosen","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.09.002_b0090","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/bju.15925","article-title":"Antegrade administration of mitomycin gel for upper tract urothelial carcinoma via percutaneous nephrostomy tube: a multi-institutional retrospective cohort study","volume":"131","author":"Rose","year":"2023","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2025.09.002_b0095","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3233\/BLC-180182","article-title":"Thermo reversible hydrogel based delivery of mitomycin C (UGN-101) for treatment of upper tract urothelial carcinoma (UTUC)","volume":"5","author":"Kleinmann","year":"2019","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.euo.2025.09.002_b0100","doi-asserted-by":"crossref","first-page":"20.e17","DOI":"10.1016\/j.urolonc.2023.07.004","article-title":"First analysis of the safety and efficacy of UGN-101 in the treatment of ureteral tumors","volume":"42","author":"Jacob","year":"2024","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2025.09.002_b0105","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.euf.2023.05.012","article-title":"Route of administration for UGN-101 and impact on oncological and safety outcomes","volume":"9","author":"Linehan","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2025.09.002_b0110","doi-asserted-by":"crossref","first-page":"147.e15","DOI":"10.1016\/j.urolonc.2022.10.029","article-title":"Early experience with UGN-101 for the treatment of upper tract urothelial cancer \u2013 a multicenter evaluation of practice patterns and outcomes","volume":"41","author":"Woldu","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2025.09.002_b0115","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.3390\/cancers16061115","article-title":"Upper tract urothelial cancer: guideline of guidelines","volume":"16","author":"Pandolfo","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.euo.2025.09.002_b0120","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.urolonc.2019.02.004","article-title":"Endocavitary treatment for upper tract urothelial carcinoma: a meta-analysis of the current literature","volume":"37","author":"Foerster","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2025.09.002_b0125","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.acuro.2022.10.002","article-title":"Management of primary upper urinary tract carcinoma in situ diagnosed by ureteroscopic biopsy: is bacillus Calmette-Guerin an alternative to nephroureterectomy?","volume":"47","author":"Territo","year":"2023","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.euo.2025.09.002_b0130","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.euf.2022.12.003","article-title":"A systematic review and meta-analysis of chemoablation for non\u2013muscle-invasive bladder cancer","volume":"9","author":"Yanagisawa","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2025.09.002_b0135","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.21037\/tau-23-35","article-title":"Adjuvant intraluminal therapies for upper tract urothelial carcinoma","volume":"12","author":"Khargi","year":"2023","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.euo.2025.09.002_b0140","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1464-410X.2012.11068.x","article-title":"Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review","volume":"110","author":"Cutress","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2025.09.002_b0145","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/j.1464-410X.2012.11066.x","article-title":"Ureteroscopic and extirpative treatment of upper urinary tract urothelial carcinoma: a 15-year comprehensive review of 160 consecutive patients","volume":"110","author":"Grasso","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2025.09.002_b0150","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/bju.15038","article-title":"CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer","volume":"125","author":"Mostafid","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2025.09.002_b0155","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1200\/JCO.22.00470","article-title":"DaBlaCa-13 study: oncological outcome of short-term, intensive chemoresection with mitomycin in nonmuscle invasive bladder cancer: primary outcome of a randomized controlled trial","volume":"41","author":"Lindgren","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.09.002_b0160","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12894-019-0482-4","article-title":"Does preoperative percutaneous nephrostomy insertion worsen upper-tract urothelial cancer oncological outcome? A retrospective single center study","volume":"19","author":"Huang","year":"2019","journal-title":"BMC Urol"},{"key":"10.1016\/j.euo.2025.09.002_b0165","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3233\/BLC-220093","article-title":"The role of local agents for the treatment of localized upper tract urothelial carcinoma: a review of the current evidence","volume":"9","author":"Asimakopoulos","year":"2023","journal-title":"Bladder Cancer"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125002378?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125002378?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:47:58Z","timestamp":1789577278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125002378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2588931125002378"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.09.002","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Systematic Review of Intracavitary Therapies for Upper Tract Urothelial Carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}